Price
No data yet.
Social Signal Score
Analyst Ratings
22 analystsRevenue
$4.59M+111.33%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kenneth H. Galbraith
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 231
- Beta
- 1.19
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -0.78
Financials
Revenue
$4.59M+111.3%Net Income
$-45.02MEBITDA
$-43.02MFree Cash Flow
$-31.95MEPS (diluted)
$-0.62Shares Outstanding (diluted)
72.99M+268.0%Operating Expenses
$51.36MCash & Debt
$270.70MReturn of Capital
$51.95MRevenue by Segment (annual)
$40.60MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $105.97M | $-81.13M | $-1.08 |
| 2024 | $76.30M | $-122.69M | $-1.62 |
| 2023 | $76.01M | $-118.67M | $-1.72 |
| 2022 | $412.48M | $124.34M | $1.91 |
| 2021 | $26.68M | $-211.84M | $-4.06 |
| 2020 | $38.95M | $-180.55M | $-3.58 |
| 2019 | $29.54M | $-145.44M | $-3.83 |
| 2018 | $53.02M | $-36.56M | $-1.26 |
| 2017 | $51.76M | $-10.41M | $-0.49 |
| 2016 | $11.01M | $-33.81M | $-1.72 |
| 2015 | $9.66M | $-19.17M | $-0.97 |
| 2014 | $1.67M | $-12.94M | $-0.65 |
Valuation
ZYMEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Neutral
Zymeworks Completes Acquisition of Theravance Biopharma VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today completed the previously announced acquisition of Theravance Biopharma. With the completion of the transaction, Theravance Biopharma is now part of Zymeworks, further advancing Zymeworks' s…
View source ↗ - Newsseekingalpha.com·9d ago·Positive
Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·27d ago·Negative
…. Zanidatamab's first-line HER2+ gastroesophageal cancer approval expands the eligible patient population and unlocks a $250M milestone plus 10–20% tiered royalties. ZYME's near-term upside hinges on commercial execution, label expansions, and integrating durable cash-flow assets like YUPELRI from the pending Theravance acquisition.
View source ↗
Earnings
Thu, Nov 5(in 6 weeks)
Consensus estimate $2.44 per share
Typical surprise -7.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.62 vs $-0.57miss
- Thu, May 7$-0.59 vs $-0.10miss
- Mon, Mar 2$-0.55 vs $-0.35miss
- Thu, Nov 6$-0.26 vs $-0.30beat
- Thu, Aug 7$0.03 vs $-0.52beat
- Thu, May 8$-0.30 vs $-0.45beat
Estimates and results for ZYME via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ZYME officers and directors.
- Bought
- $70k
- Sold
- $4.7m
1 trade
10 trades
- Hollywood Marksold
- Smith Jeffrey T Lsold
- Moore Paul Andrewsold
- Galbraith Kennethsold
- Smith Jeffrey T Lsold
- Galbraith Kennethsold
- Galbraith Kennethsold
- Moore Paul Andrewsold
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ZYME.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.